https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)60687-X.pdf

Chronic kidney disease: global dimension and perspectives

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60126-X.pdf

International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology

As the global burden of chronic kidney disease continues to increase, so does the need for a cost-effective renal replacement therapy. In many countries, patient outcomes with peritoneal dialysis are comparable to or better than those with haemodialysis, and peritoneal dialysis is also more cost-effective. These benefits have not, however, always led to increased utilization of peritoneal dialysis. Use of this therapy is increasing in some countries, including China, the USA and Thailand, but has proportionally decreased in parts of Europe and in Japan. The variable trends in peritoneal dialysis use reflect the multiple challenges in prescribing this therapy to patients. Key strategies for facilitating peritoneal dialysis utilization include implementation of policies and incentives that favour this modality, enabling the appropriate production and supply of peritoneal dialysis fluid at a low cost, and appropriate training for nephrologists to enable increased utilization of the therapy and to ensure that rates of technique failure continue to decline. Further growth in peritoneal dialysis use is required to enable this modality to become an integral part of renal replacement therapy programmes worldwide.

Changes in the worldwide epidemiology of peritoneal dialysis

Studies have estimated the average risk of postdonation ESRD for living kidney donors in the United States, but personalized estimation on the basis of donor characteristics remains unavailable. We studied 133,824 living kidney donors from 1987 to 2015, as reported to the Organ Procurement and Transplantation Network, with ESRD ascertainment via Centers for Medicare and Medicaid Services linkage, using Cox regression with late entries. Black race (hazard ratio [HR], 2.96; 95% confidence interval [95% CI], 2.25 to 3.89; P<0.001) and male sex (HR, 1.88; 95% CI, 1.50 to 2.35; P<0.001) was associated with higher risk of ESRD in donors. Among nonblack donors, older age was associated with greater risk (HR per 10 years, 1.40; 95% CI, 1.23 to 1.59; P<0.001). Among black donors, older age was not significantly associated with risk (HR, 0.88; 95% CI, 0.72 to 1.09; P=0.3). Greater body mass index was associated with higher risk (HR per 5 kg/m2, 1.61; 95% CI, 1.29 to 2.00; P<0.001). Donors who had a first-degree biological relationship to the recipient had increased risk (HR, 1.70; 95% CI, 1.24 to 2.34; P<0.01). C-statistic of the model was 0.71. Predicted 20-year risk of ESRD for the median donor was only 34 cases per 10,000 donors, but 1% of donors had predicted risk exceeding 256 cases per 10,000 donors. Risk estimation is critical for appropriate informed consent and varies substantially across living kidney donors. Greater permissiveness may be warranted in older black candidate donors; young black candidates should be evaluated carefully.

/pdf/quantifying-postdonation-risk-of-esrd-in-living-kidney-4mseegk8bt.pdf

Quantifying Postdonation Risk of ESRD in Living Kidney Donors

Extrahepatic manifestations of chronic hepatitis C.

COVID-19 has now spread to all the continents of the world with the possible exception of Antarctica. However, Africa appears different when compared with all the other continents. The absence of exponential growth and the low mortality rates contrary to that experienced in other continents, and contrary to the projections for Africa by various agencies, including the World Health Organization (WHO) has been a puzzle to many. Although Africa is the second most populous continent with an estimated 17.2% of the world's population, the continent accounts for only 5% of the total cases and 3% of the mortality. Mortality for the whole of Africa remains at a reported 19,726 as at August 01, 2020. The onset of the pandemic was later, the rate of rise has been slower and the severity of illness and case fatality rates have been lower in comparison to other continents. In addition, contrary to what had been documented in other continents, the occurrence of the renal complications in these patients also appeared to be much lower. This report documents the striking differences between the continents and within the continent of Africa itself and then attempts to explain the reasons for these differences. It is hoped that information presented in this review will help policymakers in the fight to contain the pandemic, particularly within Africa with its resource-constrained health care systems.

COVID-19 Pandemic: Is Africa Different?

Glomerular injury, occurring either as primary glomerular disease or as part of a systemic disease process, is usually a result of immune-mediated mechanisms. The morphologic reaction pattern has a diverse spectrum of appearance, ranging from normal by light microscopy in minimal change disease to crescentic forms of glomerulonephritis, with conspicuous disruption of the normal glomerular morphology. The mechanisms of glomerular immune deposit formation include trapping of circulating antigen-antibody complexes and the in situ formation of immune complexes within the glomerulus. While the majority of postinfectious immune-complex-mediated glomerulonephritides are believed to result from the deposition of circulating antigen-antibody complexes, preformed outside of the kidney and secondarily deposited in the kidney, the notion of forming in situ antigen-antibody complexes to either planted antigens or to integral structural components of the glomerulus, through "cross-reacting" autoimmune reactions, is gaining popularity in a variety of forms of glomerulonephritides. Patients with HIV infection may develop a spectrum of renal pathology, the glomerular manifestations of which include both antigen-antibody complex and nonimmune-complex-mediated pathogenetic mechanisms. Similarly, patients with Streptococcal infections, Hepatitis B virus, or Hepatitis C virus infection may develop a spectrum of glomerulonephritides, which are predominantly immune-complex-mediated. Therapy for glomerular diseases due to HIV, hepatitis B, or C virus infections remains a challenge.

Infection and glomerulonephritis

Few urinary screening studies have been performed to determine the incidence of urinary abnormalities in antiretroviral therapy-naive, HIV-infected outpatients. From published data, the incidence appears to be high, particularly when compared with populations outside sub-Saharan Africa. In South Africa, urinary screening in antiretroviral therapy clinics is not routinely practiced. The aim of this descriptive study was to screen antiretroviral therapy-naive, HIV-infected outpatients attending the HIV clinic for urinary abnormalities, namely leukocyturia, microscopic hematuria, and microalbuminuria/proteinuria. This study showed that 84% of the screened population had AIDS (CD4 count < 200 cells/ mm3), and the incidence of abnormalities on urinary dipstick testing was high: 30% had leukocyturia, 33% had microscopic hematuria, and 44% had microalbuminuria/proteinuria. In patients with leukocyturia, an infective organism was cultured in only 29.1% of cases, predominantly Escherichia coli (70%) with sterile leukocyturia comprising the remainder. There may be an association with tuberculosis (TB) or sexually transmitted infections (STI) in the sterile leucocyturia group, but this remains to be confirmed. In those with a culture positive result the most common organism was E. coli (70%), which exhibited 90% resistance to cotrimoxazole, demonstrating that cotrimoxazole prophylaxis is not effective to prevent urinary tract infection in this group. On the basis of these findings, it has been proposed that urinary screening be considered standard of care in HIV clinics in South Africa. An algorithm has been proposed for use in antiretroviral therapy clinics in South Africa to guide clinicians regarding the cost-effective management of urinary dipstick abnormalities.

Urinary screening abnormalities in antiretroviral-naive HIV-infected outpatients and implications for management--a single-center study in South Africa.

Background. Kidney disease is a major complication of HIV infection, with both acute kidney injury (AKI) and chronic kidney disease (CKD) contributing to morbidity and mortality. Incidence of AKI was reported as 5.9 per 100 patient years in ambulatory patients and ∼18% in hospitalized HIVinfected patients, an almost 3-fold higher risk compared with HIV uninfected patients in developed countries. CKD was reported in 6–48.5% of HIV-infected patients in Africa. There is a paucity of data regarding the prevalence and outcomes of AKI in HIV-infected patients in sub-Saharan Africa, the region most affected by HIV. Methods. A retrospective review of 101 HIV-positive anti-retroviral therapy (ART)-naive patients presenting with renal failure from 1 October 2005 to 30 September 2006 was undertaken. Results. A total of 684 patients presented with renal failure, 101 (14.8%) of whom were HIV positive. Ninety-nine (98%) of HIV-positive patients were black and 56 (55%) were male, with mean age 38 ± 9.9 years (range 21–61 years). HIV-positive patients demonstrated severe immunosuppression, with mean CD4 count of 135 cells/µL (range 1–579 cells/µL). Fifty-seven (56%) HIVpositive patients presented with AKI, 21 (21%) with acute-on-chronic kidney disease and 23 (23%) with CKD; seven patients with AKI were excluded due to lack of records. The causes of AKI in the HIV-positive group included sepsis (60%), volume depletion and haemodynamic instability (19%), toxins (9%), urological obstruction (7%) and miscellaneous (14%). Forty-four per cent of HIVpositive and 47% of HIV-negative patients with AKI demised; P= 0.45. Hyponatraemia (P= 0.018), acidosis (P= 0.018), anaemia (P= 0.019) and hyperphosphataemia (P= 0.003) were predictors of mortality in HIV-positive patients with AKI. In comparison, predictors of mortality in the HIV-negative group were age (P= 0.023) and black ethnicity (P= 0.04). Conclusion. HIV-positive patients, compared with the HIV-negative group, presented with AKI at a younger age and at an advanced stage of immunosuppression. Appropriate support, including dialysis, resulted in similar outcomes in both groups.

Renal failure in HIV-positive patients—a South African experience

Kidney transplantation has been established as the most effective form of renal replacement therapy from a cost and quality of life perspective in the developed world.

/pdf/uniquely-south-african-time-to-consider-offering-hiv-1xdgbesjcb.pdf

Shoyab Wadee

Papers

COVID-19 Pandemic: Is Africa Different?

Infection and glomerulonephritis

Urinary screening abnormalities in antiretroviral-naive HIV-infected outpatients and implications for management--a single-center study in South Africa.

Renal failure in HIV-positive patients—a South African experience

Uniquely South African: Time to consider offering HIV-positive donor kidneys to HIV-infected renal failure patients?